News
ASND
254.81
-1.85%
-4.81
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript
The Motley Fool · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Ascendis Pharma (ASND) and Aurinia Pharmaceuticals (AUPH)
TipRanks · 1d ago
Ascendis a new outperform at BMO on TransCon platform growth
Seeking Alpha · 2d ago
Ascendis Pharma Price Target Announced at $319.00/Share by BMO Capital
Dow Jones · 2d ago
Ascendis Pharma Initiated at Outperform by BMO Capital
Dow Jones · 2d ago
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319
Benzinga · 2d ago
BMO starts Ascendis at Outperform on further platform growth
TipRanks · 3d ago
Ascendis Pharma initiated with an Outperform at BMO Capital
TipRanks · 3d ago
Ascendis Pharma (ASND) Reports Positive Phase 2 Achondroplasia Data As Pivotal Trial Enrollment Ends
Simply Wall St · 3d ago
Weekly Report: what happened at ASND last week (0810-0814)?
Weekly Report · 4d ago
Ascendis Pharma reports Q2 EPS 90c, consensus 77c
TipRanks · 4d ago
Ascendis Pharma price target lowered to $329 from $345 at Barclays
TipRanks · 5d ago
Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next
Simply Wall St · 5d ago
Ascendis Pharma price target raised to $341 from $325 at TD Cowen
TipRanks · 5d ago
Ascendis Pharma price target raised to $290 from $280 at RBC Capital
TipRanks · 5d ago
Ascendis Pharma (NasdaqGS:ASND) Stock Turns Profitable As YORVIPATH Drives Growth
Simply Wall St · 6d ago
Ascendis Pharma Price Target Raised to $341.00/Share From $325.00 by TD Cowen
Dow Jones · 08/14 16:10
Ascendis Pharma Is Maintained at Buy by TD Cowen
Dow Jones · 08/14 16:10
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341
Benzinga · 08/14 16:00
Ascendis Pharma Price Target Raised to $290.00/Share From $280.00 by RBC Capital
Dow Jones · 08/14 15:35
More
Webull provides a variety of real-time ASND stock news. You can receive the latest news about Ascendis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASND
Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.